Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanhua Fu

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
AIDS Research and Human Retroviruses|September 2, 2025
Enhancing HIV Genotyping and Drug-Resistance Detection in Low Viral Load Samples Through Exosome Enrichment TechnologyJun Peng, Yebin Song, Zhong Chen, et al.
Expert Review of Anti-Infective Therapy|November 6, 2023
Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practiceLin Gan, Xiaoxin Xie, Yanhua Fu, et al.
Infectious Diseases and Therapy|October 16, 2023
Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort StudyLin Gan, Xiaoxin Xie, Yanhua Fu, et al.
Plos One|April 3, 2026
Real-world safety of aliskiren in primary hypertension: A cross-database studyMeirong Shan, Qian Guo, Ruofei Li, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2024
Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort studyChunmei Wang, Xiaoli Yu, Yingchun Ke, et al.
BMJ Open|July 19, 2022
Prevalence of anaemia and the associated factors among hospitalised people living with HIV receiving antiretroviral therapy in Southwest China: a cross-sectional studyGuiying Cao, Hai Long, Yuedong Liang, et al.
Iscience|March 20, 2026
A machine learning model for predicting adverse prognostic events in patients with neurosyphilis: Results from the DEFEAT-NS studyZhen Lu, Jun Zou, Hanlin Zhang, et al.
The Lancet Regional Health. Western Pacific|March 30, 2026
Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir/emtricitabine/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in ChinaXinsheng Wu, Ping Ma, Lianguo Ruan, et al.
Infectious Diseases and Therapy|June 19, 2026
Real-World Multicenter Study on the Effectiveness of Dolutegravir Plus Lamivudine in Treatment-Naive People Living with HIV with Baseline HIV-1 RNA > 500,000 Copies/mLBichen Xue, Rui Jiang, Yanyun Dou, et al.
Journal of Pharmaceutical Analysis|February 23, 2026
Large-scale evaluation of HIV-1 DNA drug resistance testing as a robust tool for clinical decision-making: A nationwide study in ChinaCaihong Wu, Limin Zhang, Zhong Chen, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
AIDS Research and Human Retroviruses|September 2, 2025
Enhancing HIV Genotyping and Drug-Resistance Detection in Low Viral Load Samples Through Exosome Enrichment TechnologyJun Peng, Yebin Song, Zhong Chen, et al.
Expert Review of Anti-Infective Therapy|November 6, 2023
Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practiceLin Gan, Xiaoxin Xie, Yanhua Fu, et al.
Infectious Diseases and Therapy|October 16, 2023
Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort StudyLin Gan, Xiaoxin Xie, Yanhua Fu, et al.
Plos One|April 3, 2026
Real-world safety of aliskiren in primary hypertension: A cross-database studyMeirong Shan, Qian Guo, Ruofei Li, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2024
Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort studyChunmei Wang, Xiaoli Yu, Yingchun Ke, et al.
BMJ Open|July 19, 2022
Prevalence of anaemia and the associated factors among hospitalised people living with HIV receiving antiretroviral therapy in Southwest China: a cross-sectional studyGuiying Cao, Hai Long, Yuedong Liang, et al.
Iscience|March 20, 2026
A machine learning model for predicting adverse prognostic events in patients with neurosyphilis: Results from the DEFEAT-NS studyZhen Lu, Jun Zou, Hanlin Zhang, et al.
The Lancet Regional Health. Western Pacific|March 30, 2026
Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir/emtricitabine/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in ChinaXinsheng Wu, Ping Ma, Lianguo Ruan, et al.
Infectious Diseases and Therapy|June 19, 2026
Real-World Multicenter Study on the Effectiveness of Dolutegravir Plus Lamivudine in Treatment-Naive People Living with HIV with Baseline HIV-1 RNA > 500,000 Copies/mLBichen Xue, Rui Jiang, Yanyun Dou, et al.
Journal of Pharmaceutical Analysis|February 23, 2026
Large-scale evaluation of HIV-1 DNA drug resistance testing as a robust tool for clinical decision-making: A nationwide study in ChinaCaihong Wu, Limin Zhang, Zhong Chen, et al.
Pageof 5